Avanir Prevails In NUEDEXTA Patent Appeal Maintaining Exclusivity Through 2026

(RTTNews) - Avanir Pharmaceuticals Inc. announced that a panel of the U.S. Court of Appeals for the Federal Circuit has upheld the validity and enforceability of Avanir's patents covering NUEDEXTA (U.S. Patent Nos. 7,659,282 and 8,227,484).

The decision confirms patent protection for NUEDEXTA until 2026 in the United States.

The Appeals Court ruling affirmed the April 2014 decision upholding the '282' and '484' patents' validity by the U.S. District Court for the District of Delaware in a lawsuit brought by Avanir against the generic manufacturers Par Pharmaceuticals, Inc. and Impax Laboratories, Inc.

NUEDEXTA remains the only FDA-approved product for the treatment of pseudobulbar affect or PBA.